Lymph Node Ratio and Kras Mutation in R Colon Cancer

Phase 3

Completed

• Conditions: Colon Cancer Stage III
• Interventions: Device: k ras; Drug: Panitumumab

• Registration Number: NCT04342676
• Lead Sponsor: Mansoura University

Brief Summary

clinical impact of LN ratio with Kras expression in colon cancer

Detailed Description

LNR and K ras were evaluated with correlated with different clinicopathological parameters of the patients, PFS and OS.

Study Timeline

• Study Start: 2017-03-10
• Primary Completion: 2019-08-25
• Study Completion: 2019-08-26
• Status Verified: 2020-04
• Study First Submitted: 2020-04-03
• Study First Submitted QC: 2020-04-08
• Last Update Submitted: 2020-04-08
• Study First Posted: 2020-04-13
• Last Update Posted: 2020-04-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 433

Inclusion Criteria

• Stage III colon cancer

Exclusion Criteria

• Stage I, II, IV

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
patients	k ras	LNR measured by (number of metastatic lymph nodes/total number of lymph nodes excised). and K ras (polymerase chain reaction (PCR) and pyrosequencing targeted for KRAS codons 12-13 was performed )
patients	Panitumumab	LNR measured by (number of metastatic lymph nodes/total number of lymph nodes excised). and K ras (polymerase chain reaction (PCR) and pyrosequencing targeted for KRAS codons 12-13 was performed )

Primary Outcome Measures

Name	Time	Method
LNR and K ras were evaluated with correlated with different clinicopathological parameters (Gender, CEA, tumor size, tumor grade and response to treatment).	2 years	impact on response

Secondary Outcome Measures

Name	Time	Method
LNR and K ras were evaluated and ASSOCIATION with PFS and OS.	2 years	impact on survival

Trial Locations

Locations (1)

Mansoura University Oncology Center; 🇪🇬 Mansoura, Ad Daqahliyah, Egypt